Company intelligence / Profile preview
Theralpha
France
- Ownership
- Private
- Development stage
- Other
01
Overview
Theralpha has advanced multiple ASIC-targeted compounds into clinical trials. As of 2014, six clinical studies had been initiated investigating ASIC involvement in various pain-related conditions, involving over 400 participants. The company's research has identified mambalgins (three-finger peptides from black mamba venom) as potential therapeutic agents that can produce pain relief comparable to morphine in preclinical models.
- Therapeutic areas
- ImmunologyCardiovascularNeurologyRheumatologyGastroenterology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Flamel Technologies (joint development agreement for controlled release formulations)
Beyond the preview
Go deeper on Theralpha.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theralpha.